Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | ATP4A | P20648 | 1/20 | 0.31 |
| ▸ | ATP4B | P51164 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14302479 | 0.81 | SMN1; SMN2 (0.36) | ALDH1A1SMN1; SMN2HTTLMNANPC1 | |
| SCHEMBL24023331 | 0.81 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2HTTLMNANPC1 | |
| SCHEMBL3085308 | 0.72 | PIK3CD (0.52) | ALDH1A1SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL2359189 | 0.70 | RAB9A (0.46) | ALDH1A1SMN1; SMN2HTTLMNANPC1 | |
| SCHEMBL1260386 | 0.70 | CCNE1 (0.37) | ALDH1A1SMN1; SMN2HTTNPC1RAB9A | |
| SCHEMBL24023268 | 0.69 | MEN1 (0.33) | ALDH1A1SMN1; SMN2HTTLMNANPC1 | |
| SCHEMBL24023338 | 0.66 | XIAP (0.34) | ALDH1A1HTTLMNANPC1RAB9A | |
| SCHEMBL1042627 | 0.65 | HSD17B1 (0.48) | HTTMAPTESR1ESR2GAA | |
| SCHEMBL1460907 | 0.65 | SMN1; SMN2 (0.56) | ALDH1A1SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL2784971 | 0.64 | GAA (0.46) | SMN1; SMN2NPC1RAB9APOLBESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799810-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799810-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7799810-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-7754746-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7754746-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-20100120865-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100120865-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100120865-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| CN-101479258-A | Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2009-07-08 | — | — | CN | disclosed |
| CN-101374823-A | Organic compounds | NOVARTIS AG (CH) | 2009-02-25 | — | — | CN | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120865-A1 | Organic compounds | PIK3C3, PIK3R3, PIK3R4 | ALDH1A1 3211/4885SMN1; SMN2 4326/4885HTT 4504/4885 |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | AKT3, PIK3R3, PIK3CD | ALDH1A1 3448/4885SMN1; SMN2 3335/4885HTT 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.